<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624205</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1414</org_study_id>
    <nct_id>NCT03624205</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of SeQuent® Please in Real World Chinese Coronary Instent Restenosis Patients</brief_title>
  <official_title>To Evaluate the Long Term Safety and Efficacy of Drug Coated Balloon SeQuent® Please in Chinese Coronary Instent Restenosis Patients,a Prospective, Multi-center,Randomization Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical International Trading Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Medical International Trading Company Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of paclitaxel -eluting PTCA-
      balloon (SeQuent® Please) in real world Chinese Coronary In Sentrestenosis patients
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure in 12 months after operation</measure>
    <time_frame>1 year</time_frame>
    <description>To measure Target Lesion Failure in 12 months by using angiography</description>
  </primary_outcome>
  <enrollment type="Actual">520</enrollment>
  <condition>Coronary In Sentrestenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel-releasing coronary balloon (SeQuent® Please)</intervention_name>
    <description>SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with coronary In sentrestenosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Criteria related to subjects

          -  At the age of 18-80, Both male and female;

          -  Patients with coronary In sentrestenosis and suitable for the theory of Drug Eluting
             PTCA Balloon Catheter（SeQuent® Please）, no more than 1 target lesion in each coronary
             artery

          -  After pre-dilation of target lesion, the residual stenosis is ≥ 30% , patients with
             type B dissection

          -  Patients must agree to sign the ICF and to undergo the clinical follow-up at 30 days,
             6 months, 6 months, 12 months, 24 months, 36months, 48 months and 60 months after
             operation Criteria related to lesions

          -  The target lesion length and target vessel diameter should be consistent with the
             instructions of Drug Eluting PTCA Balloon Catheter（SeQuent® Please）

        Exclusion Criteria:

        Criteria related to subjects

          -  Women with pregnancy or lactation

          -  Patient with cardiac shock

          -  Patients with Hemorrhagic physique or active gastrointestinal ulcers, with cerebral
             apoplexy or transient cerebral ischemia within 3 months, who couldn't be tolerated the
             expected aspirin and/or clopidogrel theory

          -  Patients with severe valvular heart disease

          -  Patients with severe congestive heart failure or NYHA class IV heart failure;

          -  Patients who have received heart transplant;

          -  Patients with life expectancy more than 60 months, or those who is difficulties in
             clinical follow-up.

          -  Patients who are currently involved in any other clinical trial;

          -  Patients that the investigators think that those are not suitable Criteria related to
             lesions

          -  Chronic total occlusion

          -  Lesion that cannot be treated with PTCA or other interventional techniques;

          -  The vessel diameter ＜ 2.25 mm

          -  Left main disease needed to be treated Exclusion criteria related to concomitant
             medication

          -  Patients who are intolerant to aspirin and/or clopidogrel or have a history of
             neutrophilopenia or thrombocytopenia, or patients with severe hepatic insufficiency
             and contraindicated for clopidogrel.

          -  Patients who are known to be intolerant or allergic to heparin, contrast agent,
             paclitaxel, iopromide, rapamycin, polylactic acid - glycolic acid polymer, stainless
             steel;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

